NCT05023343 is a Phase 4 clinical trial of Ropivacaine in Neuromuscular Blockade, sponsored by Zealand University Hospital.

Who is sponsoring NCT05023343?

NCT05023343 is sponsored by Zealand University Hospital.

What drugs are being tested in NCT05023343?

Interventions in NCT05023343: Ropivacaine, Quadriceps muscle strength, Timed Up and Go, Single-leg 6 meter timed hop test, Temperature discrimination, Pinprick test, Blood samples, Non-invasive blood pressure measurement.

What condition does NCT05023343 study?

NCT05023343 studies Neuromuscular Blockade.

Is NCT05023343 still recruiting?

NCT05023343 is currently completed. Last updated 21 December 2021.

Last reviewed 2021-12-21 · How we verify

NCT05023343

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Transmucular Quadratus Lumborum Block: Potential Quadriceps Muscle Weakness

Completed Phase 4 Last updated 21 December 2021

What this trial tests

Phase 4 trial testing Ropivacaine in Neuromuscular Blockade in 20 participants. Completed in 28 November 2021.

Timeline

2 October 2021

Primary endpoint
28 November 2021

28 November 2021

Quick facts

Lead sponsor	Zealand University Hospital
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	20
Start date	2 October 2021
Primary completion	28 November 2021
Estimated completion	28 November 2021
Sites	1 location across Denmark

Drugs / interventions tested

Ropivacaine (ROPIVACAINE) — full drug profile →
Quadriceps muscle strength
Timed Up and Go
Single-leg 6 meter timed hop test
Temperature discrimination
Pinprick test
Blood samples — full drug profile →
Non-invasive blood pressure measurement

Conditions studied

Neuromuscular Blockade — all drugs for Neuromuscular Blockade →

Sponsor

Zealand University Hospital

Who can join

18 and older, any sex, with Neuromuscular Blockade. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to examine whether the administration of the TQL block cause motor block of the lumbar plexus and thereby quadriceps muscle weakness. The investigators hypothesise that the administration of a unilateral TQL block does not cause quadriceps muscle weakness compared to a placebo block.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

No quadriceps muscle weakness following anterior quadratus lumborum block compared with placebo: a randomized, non-inferiority, blinded, volunteer trial.
Tanggaard K, Nielsen MV, Holm UHU, Hoffmann BM, et al · · 2025 · cited 1× · PMID 38754991 · DOI 10.1136/rapm-2024-105313

Verify or expand the search:

Other trials of Ropivacaine

Trials testing the same drug.

NCT07116343 — Intrapleural Ropivacaine Infusion in Cardiac Surgery · Phase 4 · recruiting
NCT07209345 — Pre-emptive Scalp Infiltration With Low-dose Flurbiprofen and Ropivacaine for Postoperative Analgesia After Craniotomy · NA · recruiting
NCT05642026 — INTERCOSTAL NERVE BLOCK: Efficacy of CINB for Patients With Multiple Rib Fractures · Phase 4 · recruiting
NCT07013526 — Dexmedetomidine as Adjuvant for Suprazygomatic Maxillary Nerve Block in Children's Adenotonsillectomy · NA · not yet recruiting
NCT06925789 — Influence of Standardized Perioperative Anesthetic, Analgesic Care on Outcome of Patients Undergoing Hip Fracture Surger · Phase 1 · withdrawn

Other recruiting trials for Neuromuscular Blockade

Currently open trials in the same condition.

NCT07203287 — Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease · Phase 4 · recruiting
NCT06945341 — International Focus Group Discussion on Neuromuscular Monitoring. · recruiting
NCT06948409 — NMBA Reversal and Postoperative Urinary Retention · active not recruiting
NCT07003061 — Sarcopenia and Neuromuscular Block in Gastrointestinal Cancer Surgery · recruiting
NCT06679569 — Deep Neuromuscular Blockade on Postoperative Pain · NA · recruiting

Other Zealand University Hospital trials

Trials by the same sponsor.

NCT07373561 — Post-Intensive Care Syndrome and Associated Symptom Burden Among Danish ICU Survivors · not yet recruiting
NCT07386080 — Carbergoline for Antipsychotic Induced Hyperprolactinemia. · Phase 4 · not yet recruiting
NCT07482150 — The Connect Trial: Connecting Hospital Patients to Alcohol Care · NA · not yet recruiting
NCT07460999 — Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC) · NA · recruiting
NCT07365527 — Sonoporation and Tumor Microenvironment Response in Colorectal Liver Metastases · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05023343 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zealand University Hospital
Last refreshed: 21 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05023343.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing